Navigation Links
AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet
Date:6/8/2009

Amerinet Offering AccuVein's AV300 Hand-Held Vein Illumination Device to Membership

COLD SPRING HARBOR, N.Y., June 8 /PRNewswire/ -- AccuVein LLC today announced a three year agreement with Amerinet Inc. to offer the AccuVein AV300, the world's first hand-held, non-contact vein illumination device to its members. The AccuVein AV300 projects a pattern of light on a patient's skin revealing vein position to help the healthcare professional locate veins for blood draw (venipuncture), IV starts and blood donation.

"Amerinet's network will help us introduce the AccuVein AV300 into health care facilities across the nation supporting our goal to provide all health professionals with a device that may reduce time and effort in establishing an IV line," said Stephen P. Conlon, President, AccuVein.

"The AccuVein AV300 embodies the types of tools we prefer to offer, with an eye to helping reduce healthcare costs and improving healthcare quality," said Randall (Randy) Walter, Executive Vice President, Contracting, Enterprise Solutions, Inquisit and Marketing, Amerinet Inc. Amerinet is a leading national healthcare group purchasing organization of over 30,000 members, including hospitals, physician offices, surgery centers, EMT/Emergency Medicine and Long Term Care sites.

About AccuVein

AccuVein applies advanced technologies to important healthcare challenges. Their innovative AV300 allows practitioners to see a map on the patient's skin of the position of veins, helping caregivers locate veins while they perform the most common invasive medical procedure -- venipuncture. Built using AccuVein's expertise in medical device miniaturization and user-intuitive design, the AV300 is the world's first portable, non-contact vein illumination solution. With more than a dozen patents filed worldwide, AccuVein demonstrates an ongoing commitment to invest in improving patient care and patient satisfaction.

For more information on the AccuVein AV300, please visit www.AccuVein.com.

About Amerinet

As a leading group purchasing organization, Amerinet strategically partners with healthcare providers to reduce costs and improve quality.

Through its Total Spend Management solutions and operational performance improvement programs, tools and services, Amerinet assists members in their efforts to reduce costs, improve efficiencies and create new revenue streams. Supported by a team of clinical, data and supply chain experts, Amerinet offers a comprehensive portfolio of product and service contracts to address members' specific needs.

Based in St. Louis, Amerinet serves acute and alternate care site healthcare providers nationwide. To learn more, visit www.amerinet-gpo.com.


'/>"/>
SOURCE AccuVein
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology International Receives License to Manufacture Products
2. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
3. Call for papers for Pira International's Global Crop Protection Summit 2009
4. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
5. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
6. As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention
7. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
8. Rodobo International, Inc. Reports Q2 and First Half of 2009
9. Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22
10. Professor Wing Wong Elected to the National Academy of Sciences
11. PRA International Participating in Pharmacoeconomics and Outcomes Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):